March 2024. Volume 20. Number 1

The new ‘Oppenheimer’ against HIV: dolutegravir

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Bacha JM, Dlamini S, Anabwani F, Gwimile J, Kanywa JB, Farirai J, et al. Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa. Pediatr Infect Dis J. 2023;42:576-81.

Reviewers: Martín Masot R1, Llerena Santa Cruz E2.
1UGC Pediatría. Hospital Regional Universitario de Málaga. Málaga. España.
2Pediatra CAP La Torrassa. L'Hospitalet de Llobregat. Barcelona. Hospital Joan XXIII . Tarragona. España.
Correspondence: Rafael Martín Masot. Email: rafammgr@gmail.com
Reception date: 28/12/2023
Acceptance date: 08/01/2024
Publication date: 07/02/2024

Abstract

Authors´ conclusions: we found dolutegravir (DTG) to be highly effective and safe within our cohort of children and adolescents living with HIV (CALHIV) in low-and middle-income countries. These findings can empower clinicians to prescribe DTG confidently to eligible CALHIV.

Reviewers’ commentary: dolutegravir has a high rate of viral suppression with a few adverse effects, so it could be an option to consider in settings without access to antiretroviral therapy in children over 20 kg, either as first or second line treatment.

How to cite this article

Martín Masot R, Llerena Santa Cruz E. Dolutegravir es el nuevo “Oppenheimer” contra el VIH. Evid Pediatr. 2024;20:7.

AVC | Critically appraised articles

Bacha JM, Dlamini S, Anabwani F, Gwimile J, Kanywa JB, Farirai J, et al. Realizing the Promise of Dolutegravir in Effectively Treating Children and Adolescents Living With HIV in Real-world Settings in 6 Countries in Eastern and Southern Africa. Pediatr Infect Dis J. 2023;42:576-81.

Reviewers: Martín Masot R1, Llerena Santa Cruz E2.
1UGC Pediatría. Hospital Regional Universitario de Málaga. Málaga. España.
2Pediatra CAP La Torrassa. L'Hospitalet de Llobregat. Barcelona. Hospital Joan XXIII . Tarragona. España.
Correspondence: Rafael Martín Masot. Email: rafammgr@gmail.com
Reception date: 28/12/2023
Acceptance date: 08/01/2024
Publication date: 07/02/2024

How to cite this article

Martín Masot R, Llerena Santa Cruz E. Dolutegravir es el nuevo “Oppenheimer” contra el VIH. Evid Pediatr. 2024;20:7.

07/02/2024

Linked Comment